Abstract
Growth differentiation factor 5 (GDF5) is a member of the bone morphogenic protein (BMP) family and plays critical roles in organ development processes including bone, cartilage, ligament, and joint formation. GDF5 is expressed in the cartilage primordium in the early limb development, and in the interzone of joint formation sites. GDF5 is also observed in adult tissue and cell lines. This spatialtemporal expression pattern of GDF5 proves its essential role in the formation of bone and cartilage. Similar to other members of BMPs, the signaling cascade of GDF5 is originated through binding to type I and type II receptors and thus regulating the downstream intracellular biochemical processes. Mutations of GDF5 are associated with several human and animal diseases that are characterized by skeletal deformity such as short digits and short limbs. In vitro and in vivo studies demonstrated that overexpression of GDF5 or administration of recombinant protein promotes chondrogenesis and osteogenesis. Moreover, a promising feature of GDF5 is osteoinduction, which is used in tissue engineering for bone repair with or without a carrier in animal platforms and in human preclinical settings. The exciting results signify that GDF5 is a compelling candidate for bone tissue engineering by enhancing osteogenesis and angiogenesis. In this review, we will focus the discussion on the basic structure, signaling pathways, function in cartilage and bone formation, and potential clinical application of GDF5 in bone tissue regeneration.
Keywords: GDF5, BMP, bone tissue engineering and regeneration, bone formation, joint formation, osteogenesis, chondrogenesis, angiogenesis.
Current Pharmaceutical Design
Title:Growth Differentiation Factor 5 Regulation in Bone Regeneration
Volume: 19 Issue: 19
Author(s): Li Jin and Xudong Li
Affiliation:
Keywords: GDF5, BMP, bone tissue engineering and regeneration, bone formation, joint formation, osteogenesis, chondrogenesis, angiogenesis.
Abstract: Growth differentiation factor 5 (GDF5) is a member of the bone morphogenic protein (BMP) family and plays critical roles in organ development processes including bone, cartilage, ligament, and joint formation. GDF5 is expressed in the cartilage primordium in the early limb development, and in the interzone of joint formation sites. GDF5 is also observed in adult tissue and cell lines. This spatialtemporal expression pattern of GDF5 proves its essential role in the formation of bone and cartilage. Similar to other members of BMPs, the signaling cascade of GDF5 is originated through binding to type I and type II receptors and thus regulating the downstream intracellular biochemical processes. Mutations of GDF5 are associated with several human and animal diseases that are characterized by skeletal deformity such as short digits and short limbs. In vitro and in vivo studies demonstrated that overexpression of GDF5 or administration of recombinant protein promotes chondrogenesis and osteogenesis. Moreover, a promising feature of GDF5 is osteoinduction, which is used in tissue engineering for bone repair with or without a carrier in animal platforms and in human preclinical settings. The exciting results signify that GDF5 is a compelling candidate for bone tissue engineering by enhancing osteogenesis and angiogenesis. In this review, we will focus the discussion on the basic structure, signaling pathways, function in cartilage and bone formation, and potential clinical application of GDF5 in bone tissue regeneration.
Export Options
About this article
Cite this article as:
Jin Li and Li Xudong, Growth Differentiation Factor 5 Regulation in Bone Regeneration, Current Pharmaceutical Design 2013; 19 (19) . https://dx.doi.org/10.2174/1381612811319190003
DOI https://dx.doi.org/10.2174/1381612811319190003 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Value of Abnormal Fetal Cardiac Axis in the Fetal Congenital Heart Disease
Current Medical Imaging First Trimester Tricuspid Regurgitation: Clinical Significance
Current Cardiology Reviews Metabolic Syndrome Targets
Current Drug Targets - CNS & Neurological Disorders Voltage-Gated Sodium Channels as Therapeutic Targets for Treatment of Painful Diabetic Neuropathy
Mini-Reviews in Medicinal Chemistry DNA Methylation, An Epigenetic Mode of Gene Expression Regulation in Reproductive Science
Current Pharmaceutical Design Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry
Medicinal Chemistry Hereditary Haemorrhagic Telangiectasia: A Rare Disease As A Model for the Study of Human Atherosclerosis
Current Pharmaceutical Design The Use of Anti-Epileptic Medication in Women with Affective Disorders in Early and Late Pregnancy and During Breastfeeding
Current Women`s Health Reviews The Fetal Cardiac Function
Current Cardiology Reviews Effects of Thyroid Hormones on Memory and on Na+, K+-ATPase Activity in Rat Brain
Current Neurovascular Research Mechanisms Involved in the Genesis of Diabetic Nephropathy
Current Diabetes Reviews Determinants of Human Coronary Collaterals
Current Cardiology Reviews Efficacy and Safety Analysis of Botox Application and Iatrogenic Botulism: Panacea or Peril?
Current Pharmaceutical Design Complex Obesity
Current Pediatric Reviews Arrhythmias and Left Ventricular Hypertrabeculation/Noncompaction
Current Pharmaceutical Design Reactive Species, Cellular Repair and Risk Factors in the Onset of Type 2 Diabetes Mellitus: Review and Hypothesis
Current Diabetes Reviews Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Pharmacologic Treatment of Pulmonary Arterial Hypertension
Current Pharmaceutical Design Glucose-6-Phosphate Dehydrogenase Deficiency: Disadvantages and Possible Benefits
Cardiovascular & Hematological Disorders-Drug Targets Nuchal Translucency and Congenital Heart Defects
Current Cardiology Reviews